ACTRN12621000532808已完成未知
Immunogenicity of the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and the BNT162b2 (Pfizer) COVID-19 Vaccines in a South Australian Cohort of Immunocompromised Patients and their Close Household Contacts
Central Adelaide Local Health Network0 个研究点目标入组 176 人开始时间: 2021年5月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 176
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •For patient group:
- •Have a current kidney transplant >3 months or currently on dialysis.
- •Have a close household contact able to participate.
排除标准
- •For patient group:
- •Prior exposure to SARS-CoV-2 (positive serology).
- •Have previously received a COVID-19 vaccination.
- •Due to receive a transplant within the ensuing 6 months.
- •Control/comparison group:
- •Prior exposure to SARS-CoV-2 (positive serology).
- •Have previously received a COVID-19 vaccination.
研究者
相似试验
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Hemodialysis Patients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in hemodialysis patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, Hemodialysis patients, wild-type, delta variant, antibody, T-cell responseTCTR20211026002Kao Tun Roke Foundation130
招募中
不适用
Comparison of the Immunogenicity of ChAdOx1 nCoV-19 (COVID-19) Vaccine against the Wild-Type and Delta Variant in Kidney Transplant Recipients and Healthy VolunteersImmune response after ChAdOx1 nCoV-19 Vaccine in kidney transplant patients compared to healthy volunteers.Immune response, ChAdOx1 nCoV-19 Vaccine, kidney transplant patients, Wuhan Strain, B.1.617.2 (Delta) Variant, antibody, T-cell responseTCTR20211025004Kao Tun Roke Foundation200
已完成
4 期
Immunogenicity and safety of ChAdOx1 vaccine (Covid-19 vaccine) in Thai people with underlying diseaseDiabetes mellitusCirrhosissolid cancerHematologic malignancychronic kidney diseaserheumatological diseasecardiovascular diseaseChAdOx1 vaccineimmunogenicitycovid-19 vaccineTCTR20211228003Chulabhorn Royal Academy385
招募中
不适用
To determine the safety and antibody performance in Indian adults after taking COVID-19 vaccine.CTRI/2021/03/031998Advanced Cancer for Treatment Research and Education in cancer and Tata Memorial Centre
招募中
2 期
Immune response of booster dose with ChAdOx-1 in adult who had received 2 doses of CoronaVac (COVID-19)Prevention of COVID-19 with booster-dose strategy among healthy adult who received 2-dose of Coronavac using ChAdOx1 nCoV-19 vaccine.COVID-19 Vaccine, AstraZeneca Booster , Fractional low dose vaccineTCTR20210722003Health and Aging Platform, Chulalongkorn University400